Author name: Leonardo Arias

The FDA has granted a three-month extension for Capricor Therapeutics’ Duchenne muscular dystrophy hopeful deramiocel in order to review additional data and consider a refined indication. The new target action date for the therapy is November 22.

Sondermind and Limbic are evaluating digital health devices intended to help with anxiety and depression.

The two countries failed to reach an agreement before Saturday’s deadline for the Section 338 levies, with Canada vowing to “match those tariffs dollar for dollar.” 

The FDA has placed a clinical hold on RGX-121 after small nodules or cystic masses were detected in the spines of five patients enrolled in REGENXBIO’s registrational trial. The biotech no longer plans to resubmit the candidate—which was rejected in February—in the near term.

Roche, through its subsidiary Genentech, will gain access to the investigational asset HM17321, which is designed to not only elicit weight loss but also improve lean mass.

Not much is known about Boehringer Ingelheim’s drug candidate, dubbed BI 3031185, though the asset has completed at least two other Phase 1 studies this year.

The current classifications of vaccine recommendations could imply that not all shots require the consent of patients or their parents, according to Health Secretary Robert F. Kennedy Jr.

We’ve been building the PBM of the future. Let me share what that means.

Care coordination starts by designing healthcare around people, not disconnected systems.

En 2006, un grupo de biólogos marinos frente a las costas de Islandia recogió un ejemplar de almeja de Islandia (Arctica islandica). Al contar los anillos de crecimiento de su concha —un método similar a la dendrocronología en los árboles— descubrieron …